Market Place
Sourcing Support
Olverembatinib Data Reaffirms Potential in Ponatinib Resistance
10 Dec 2024 //
PR NEWSWIRE
Novartis` Scemblix leaps into newly diagnosed CML
30 Oct 2024 //
FIERCE PHARMA
Novartis Scemblix® Approved for Newly Diagnosed CML
29 Oct 2024 //
GLOBENEWSWIRE
Takeda circles Ascentage`s Scemblix challenger for up to $1.3B
15 Jun 2024 //
FIERCE PHARMA
Novartis Highlights Scemblix CML Innovation At ASCO, EHA With Phase III Data
15 May 2024 //
GLOBENEWSWIRE
Novartis gears up for key expansions of 3 cancer drugs
24 Apr 2024 //
FIERCE PHARMA
Novartis Scemblix shows superior MMR rates vs. TKIs in Phase III trial
08 Jan 2024 //
GLOBENEWSWIRE
Novartis showcases significant data updates from Kisqali, iptacopan and Scemblix
20 Nov 2023 //
GLOBENEWSWIRE
Scemblix`s Scemblix (asciminib) Receives Approval in Europe
02 Mar 2023 //
EMA
Novartis`s Scemblix (asciminib) Receives Approval in Europe
07 Sep 2022 //
EMA
Scemblix™, a first-in-class CML treatment with new mechanism of action approved
31 Aug 2022 //
NEWSWIRE
Novartis receives vital licence for Scemblix
17 Jun 2022 //
PHARMATIMES
Access to Novartis treatment for Myeloid leukaemia patients
25 Jan 2022 //
PHARMATIMES
Novartis scores new CML OK for `wild card` STAMP inhibitor
30 Oct 2021 //
ENDPTS
FDA approves Novartis Scemblix® (asciminib), with novel MOA
29 Oct 2021 //
NOVARTIS
Asciminib Improves Health-Related Quality of Life in Patients With Chronic ML
14 Sep 2021 //
FIRSTWORDPHARMA
Novartis` asciminib tops Pfizer`s Bosulif in head-to-head trial
08 Dec 2020 //
FIERCE BIOTECH
Novartis reports positive data of asciminib in ASCEMBL trial
27 Aug 2020 //
CLINICALTRIALSARENA
Novartis` asciminib bests Pfizer`s Bosulif in phase 3 leukemia trial
27 Aug 2020 //
FIERCE BIOTECH
Novartis’ phase III ASCEMBL study of asciminib vs bosutinib meets primary
26 Aug 2020 //
PHARMABIZ
Asciminib in Relapsed Chronic Myeloid Leukemia
03 Apr 2020 //
NEJM
Novartis rethinks CML strategy for next-gen allosteric drug
29 Jan 2020 //
ENDPTS
I-Mab Biopharma, ABL Bio Announce Collaboration on Bispecific Antibodies
26 Jul 2018 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.